Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence of S282T mutation in different genotypes of hepatitis C virus from DAA-treated naïve Chinese patients who were chronically infected with HCV.

European review for medical and pharmacological sciences - 1 Aug 2018

Qiao B, Tong Y-Q, Wang M, Gong W-J, Li Y

Abstract excerpt

OBJECTIVE: Although direct-acting antiviral agents (DAAs) for treating hepatitis C virus (HCV) infection have not yet been approved for clinical application at present in China, the development trend is irresistible. DAAs-containing therapeutic regimens have been approved and others are also under development worldwide. In vitro studies have shown that S282T mutation in the NS5B region of HCV is involved in DAAs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to China

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Genotype

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Mutation

Share to Prevalence

Source

Identifiers

PMID: 30178855
DOI: 10.26355/eurrev_201808_15730

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of S282T mutation in different genotypes of hepatitis C virus from DAA-treated naïve Chinese patients who were chronically infected with HCV.PMID 30178855Read ↗

Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western ChinaSemantic proximity Read ↗

Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China.Semantic proximity Read ↗

Comparison of Naturally Occurring Resistance-Associated Substitutions Between 2008 and 2016 in Chinese Patients with Chronic Hepatitis C Virus InfectionSemantic proximity Read ↗

[Clinical significance of drug resistance-associated mutations in treatment of hepatitis C with direct-acting antiviral agents].Semantic proximity Read ↗

Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan.Semantic proximity Read ↗

Analysis of Naturally Occurring Resistance-Associated Variants to NS3/4A Protein Inhibitors, NS5A Protein Inhibitors, and NS5B Polymerase Inhibitors in Patients With Chronic Hepatitis C.Semantic proximity Read ↗

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and ChallengesSemantic proximity Read ↗

Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) at baseline of treatment in thalassemia patients: a referral center study.Semantic proximity Read ↗

Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus.Semantic proximity Read ↗

Prevalence of resistant associated variants (RAVs) in the naïve HCV patient candidate for direct acting antiviral (DAA) therapy.Semantic proximity Read ↗

Analysis of drug-resistance-associated mutations and genetic barriers in hepatitis C virus NS5B sequences in China.Semantic proximity Read ↗

[Safety and efficacy of DCV-based DAAs therapy for chronic HCV infection in China].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.